Terminated PHASE2 INTERVENTIONAL 2-arm NCT00910299

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI) (TRIGGER-PCI)

Effectiveness of Prasugrel Versus Clopidogrel in Subjects With High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stent

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Coronary Artery Disease (CAD)

Interventions Clopidogrel Prasugrel

Updated 8 times since 2017 Last updated: May 8, 2012 Started: Jul 31, 2009 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to the low rate of primary endpoint events experienced in the study to date

Other terminated trials from Daiichi Sankyo Co., Ltd.

More terminations from Daiichi Sankyo Co., Ltd.

This PHASE2 trial investigates Coronary Artery Disease (CAD) and is currently terminated or withdrawn. Daiichi Sankyo Co., Ltd. leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Berka, Germany , Bad Krozingen, Germany , Bad Segeberg, Germany , Berlin, Germany , Bremen, Germany , Clearwater, United States , Dortmund, Germany , Essen, Germany , Freiburg im Breisgau, Germany , Fulda, Germany and 17 more locations